Reports $709 million in preliminary1 full-year 2024 U.S. net product revenues$611 million in SYFOVRE® U.S. net product revenues, including $167 ...

Across all DME patients dosed to date, 4D-150 continues to be well tolerated with no intraocular inflammation observed at any timepoint or dose ...